Bal Pharma (BALPH) is engaged in the research, development, manufacture and marketing of bulk drugs, intermediates, tablets, capsules, fluids, opthalmic solutions, and parenterals. Incorporated as a private limited company on May 19, 1987, it was converted into a public limited company on Aug. 9, 1994. The company has been jointly promoted by Ghevarchand Surana of Micro Labs Group, which has a turnover in excess of Rs 3,000 million with a ranking of 20 in the Indian Pharma Industry and the Dubai-based Siroya family with business activities spanning construction, jewelry, mining, garments, umbrellas and general trading.
The ISO 9001:2000 certified company operates through its ethical, servetus, generics, bulk drug, bal vedics and export divisions offering branded formulation products mainly for diabetes and cardiac care like Pantofix and Zanozole, Diagrm-40 and 80 for better management of diabetes, Lipofix-R, and ayurvedic products like Menoleap and Anarsha. Two manufacturing units are located in Bangalore, one in Pune and a new unit in Uttaranchal with installed capacities of 650 million tablets, 38 MTPA bulk drugs, 100 million capsules, 75 MTPA ointment units, 19 million eye drop units, 7 million intravenous units and 750 Kl liquids. The company is one of only four companies in India with FFS technology for small volume parenterals.
It was successful in getting its bulk drugs registered in Japan. A major R&D project was the manufacture of an intermediate for Gliclazide. In this connection, funding was provided for pilot plant studies and scale-up from the Department of Scientific and Industrial Research, Government of India. Products are exported to countries like Australia, Belgium, Canada, Egypt, France, Hungary, Korea, Malaysia, Pakistan, Switzerland, Thailand, UAE and UK and the recently tapped markets of Latin America and Africa. The re
Using our Today Bank Nifty Prediction will help you daily make money with our Bank Nifty options as we are #1 Bank Nifty tips providers in India.
